J3387 Elivaldogene Autotemcel Reimbursement

HCPCS Level II code J3387 designates the injectable gene therapy product elivaldogene autotemcel, billed per treatment. As a single-administration biologic therapy for a defined rare disease indication, this code is important for payers, providers, and pharmacies that manage high-cost, one-time or limited-course gene therapies. Nationally, accurate use of J3387 affects coverage determinations, prior authorization workflows, and billing reconciliation for specialty infusion and inpatient services.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the therapy, the typical sites of service where the product is administered, and the payer landscape with respect to coverage practice. The publication highlights billing benchmarks, common claims processing considerations, and relevant policy updates that influence reimbursement and utilization management for advanced biologics billed under J3387.

This summary provides clinicians, revenue cycle managers, and policy analysts with a concise reference to the code's clinical purpose, billing implications, and the payer groups most directly involved in coverage and payment decisions.

Billing Code Overview

HCPCS Level II code J3387 represents an injectable gene therapy product described as Injection, elivaldogene autotemcel, per treatment. This code covers the administration of the specified gene therapy as a single treatment episode.

Service type: Drug administration for a gene therapy product
Typical site of service: Hospital inpatient or outpatient infusion center, specialty clinic, or other settings equipped for advanced biologic infusions

Data not available in the input.

Clinical Context

A 6-year-old child with a confirmed diagnosis of a rare, severe monogenic neurologic disorder undergoes a one-time gene therapy administration of elivaldogene autotemcel. The child is transported to a specialized pediatric cellular-therapy infusion center or a hospital outpatient infusion suite that supports advanced biologic therapies. Pre-treatment workup includes verification of eligibility criteria, baseline neurologic and laboratory assessments, infectious disease screening, and informed consent by the guardian. On the day of treatment, the patient is admitted to a monitored infusion area; a multidisciplinary team including a pediatric hematologist/oncologist or gene-therapy specialist, a pediatric nurse experienced in cellular therapies, pharmacy personnel, and a transplant/cell-therapy coordinator performs product verification, dosing calculation, and bedside infusion. The product is administered as a single treatment event (per treatment), with continuous monitoring for infusion reactions and early post-infusion complications. Post-infusion observation typically includes short-term monitoring in the infusion center or hospital, scheduled neurologic and laboratory follow-up visits, and long-term outcome surveillance per the gene-therapy manufacturer and institutional protocols.

Coding Specifications

Modifier	Description	When to Use
`52`	Reduced Services	Use when the full scope of the infusion or associated service is partially reduced compared with the usual service delivered.

Taxonomy Code	Specialty	Notes
`2080P0208X`	Pediatric Hematology-Oncology	Clinicians who manage pediatric cellular and gene therapies.
`2086S0112X`	Clinical Molecular Genetics	Specialists involved in genetic diagnosis and eligibility assessment for gene therapy.
`2084P0800X`	Pediatric Medicine	Primary pediatricians coordinating peri-infusion care and follow-up.
`363L00000X`	Transplant Immunology	Providers overseeing immune monitoring and transplant-like peri-procedural management.
`207K00000X`	Pharmacy	Specialty pharmacists who prepare, handle, and verify cellular therapy products.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G12.2`	Motor neuron disease	Represents progressive neuromuscular conditions that may be targets for investigational or approved gene therapies.
`G31.8`	Other specified degenerative diseases of nervous system	Captures rare neurodegenerative genetic disorders for which gene therapy may be indicated.
`E75.2`	Other sphingolipidosis	Genetic metabolic disorders that can present early and may be treated with advanced therapies in some protocols.
`E75.0`	Gangliosidosis and related disorders	Specific lysosomal storage disorders potentially managed with gene-modifying treatments.
`Q87.1`	Congenital malformation syndromes predominantly affecting facial appearance	Example congenital genetic syndromes that may be part of differential diagnoses in genetic-testing pathways leading to gene-therapy consideration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	May be used for billing intravenous infusion time and nursing administration components when facility uses oncology infusion administration codes alongside gene-therapy product billing.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary infusion)	Used to report additional monitored infusion time beyond the initial hour if applicable to supportive infusions or extended observation.
`36415`	Collection of venous blood by venipuncture	Used for pre-infusion and post-infusion laboratory monitoring blood draws.
`36561`	Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older	Used when a central venous access device is placed for administration of the gene-therapy product.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	May apply to administration of supportive biologic or adjunctive injections associated with the treatment visit when relevant.

OpenPayer

Summary & Overview

HCPCS J3387: Injection, elivaldogene autotemcel, per treatment